Revolutionizing Obesity Treatment | Metsera
Discover scalable, innovative therapies for obesity. Our next-gen NuSH treatments offer effective, convenient solutions to empower lasting weight loss. Learn more today!
Metsera eyes $289M IPO to fund phase 3 weight loss trial
4 days ago · Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks ... The biotech recently linked the injectable candidate to weight loss of up to 11.3% after 12 weeks ...
Weight-loss drug developer Metsera targets up to $1.78 billion ...
4 days ago · Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...
Metsera links GLP-1 drug to 11% weight loss after 12 weeks
Jan 7, 2025 · Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some of its $215 million war chest to assess monthly dosing of the...
Metsera Touts ‘Powerful’ Weight Loss Results—Again
Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 weeks, with no plateau and a promising safety profile.
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 · For patients receiving Metsera’s investigational injection at the 1.2-mg dose, weight loss continued after 36 days, with an 8.1% cumulative weight loss at Day 57, or four weeks after the...
Metsera reveals data supporting long-acting obesity shot
Jan 7, 2025 · Privately-held biotechnology startup Metsera said Tuesday a long-acting GLP-1 shot it’s developing helped people who are overweight or have obesity lose more weight than placebo recipients in a Phase 2 trial.
Metsera links long-acting GLP-1 shot to 7.5% weight loss at 36 …
Jan 2, 2025 · For patients receiving Metsera’s investigational injection at the 1.2-mg dose, weight loss continued after 36 days, with an 8.1% cumulative weight loss at Day 57, or four weeks after the final dose, the biotech said in today’s release.
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss …
Sep 24, 2024 · Five months after launching, Metsera is making waves with Phase I results for a long-acting GLP-1 injectable showing a 7.5% reduction in body weight at day 36. The biotech said the results were as good as or better than approved or other similar clinical-stage GLP-1 compounds out there now.
Metsera’s touts ‘powerful’ weight loss results — again
Jan 7, 2025 · Months after posting weight loss of 7.5 percent at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11 percent average body weight reduction at 12 weeks, with no plateau and a promising safety profile.